Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $9.00.

A number of research firms have issued reports on PYXS. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Pyxis Oncology in a report on Monday, May 19th. Royal Bank Of Canada restated an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th.

Hedge Funds Weigh In On Pyxis Oncology

A number of institutional investors have recently modified their holdings of PYXS. Commonwealth Equity Services LLC raised its position in shares of Pyxis Oncology by 61.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company's stock worth $41,000 after purchasing an additional 10,000 shares during the period. American Century Companies Inc. raised its position in shares of Pyxis Oncology by 88.1% during the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock worth $468,000 after purchasing an additional 140,498 shares during the period. Sei Investments Co. acquired a new position in shares of Pyxis Oncology during the fourth quarter worth approximately $95,000. Aristides Capital LLC acquired a new position in shares of Pyxis Oncology during the fourth quarter worth approximately $193,000. Finally, Renaissance Technologies LLC raised its position in shares of Pyxis Oncology by 83.0% during the fourth quarter. Renaissance Technologies LLC now owns 293,354 shares of the company's stock worth $458,000 after purchasing an additional 133,018 shares during the period. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Trading Down 1.3%

PYXS stock traded down $0.02 during trading on Monday, hitting $1.18. The company had a trading volume of 83,678 shares, compared to its average volume of 740,048. The business has a 50-day moving average of $1.14 and a 200-day moving average of $1.30. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39. The stock has a market cap of $72.79 million, a PE ratio of -0.74 and a beta of 1.18.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.06). Research analysts forecast that Pyxis Oncology will post -1.04 EPS for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.